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Few prognostic factors have been associated with glio-
blastoma survival. We analyzed a complete tagging of
the epidermal growth factor (EGF) and EGF receptor
(EGFR) gene polymorphisms as potential prognostic
factors. Thirty tagging single-nucleotide polymorphisms
(SNPs) in EGF and 89 tagging SNPs in EGFR were ana-
lyzed for association with survival in 176 glioblastoma
cases. Validation analyses were performed for 4
SNPs in a set of 638 glioblastoma patients recruited
at The University of Texas M. D. Anderson Cancer
Center (MDACC). Three hundred and seventy-four glio-
blastoma patients aged 50 years or older at diagnosis
were subanalyzed to enrich for de novo arising glioblas-
toma. We found 7 SNPs in haplotype 4 in EGF that were
associated with prognosis in glioblastoma patients. In
EGFR, 4 of 89 SNPs were signiﬁcantly associated with
prognosis but judged as false positives. Four of the sig-
niﬁcantly associated EGF polymorphisms in haplotype
block 4 were validated in a set from MDACC;
however, none of the associations were clearly repli-
cated. rs379644 had a hazard ratio (HR) of 1.19
(0.94–1.51) in the whole population with 18.6 months
survival in the risk genotype compared with 24.5 in
the reference category. As the median age differed
slightly between the 2 study sets, the MDACC cases
aged 50 or older at diagnosis were analyzed separately
(rs379644, HR 1.32 [0.99–1.78]), which is marginally
signiﬁcant and partially validates our ﬁndings. This
studyis, to our knowledge,the ﬁrstto perform acompre-
hensive tagging of the EGF and EGFR genes, and the
data give some support that EGF polymorphisms
might be associated with poor prognosis. Further conﬁr-
mation in independent data sets of prospective studies is
necessary to establish EGF as prognostic risk factor.
Keywords: EGF, EGFR, glioblastoma, outcome,
polymorphism.
G
lioblastoma is the most common and aggressive
type of glioma. It is associated with poor progno-
sis; however, few prognostic factors have been
identiﬁed apart from age, Karnofsky performance
status, and MGMT hypermethylation status. Low pene-
trance genes (single-nucleotide polymorphisms [SNPs])
in epidermal growth factor (EGF)
1,2 have been reported
to be prognostic factors, and previous studies have inves-
tigated a smaller set of polymorphism in immune func-
tion genes such as interleukin 4 (IL4),
3 HTERT,
4,5 and
glutathione metabolism.
3,6 Few previous studies have
investigated genes by complete gene tagging. An associ-
ation with poor survival of glioblastoma patients and a
functional polymorphism, the 61 A/G located in the
EGF promoter, was observed in a small study including
42 patients with glioblastoma,
1 but 2 other studies have
failed to replicate the initial observation in 197 and 200
glioblastoma cases, respectively.
2,7 In a normal tissue,
the ligand EGF binds to the EGF receptor (EGFR), indu-
cing a dimerization of one or several members of the
EGF receptor family (ErbB 1–4), activating several
tyrosine kinases and other downstream signal molecules
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gene plays a key role in the glioma progression
pathway and is ampliﬁed in approximately 30%–50%
of malignant gliomas. Glioblastoma with EGFR ampli-
ﬁcations often contain a genetic mutation of EGFR
(EGFRvIII); this mutation alters the receptor domain
and renders the receptor to be constitutively active by
phosphorylation.
8 EGFR overexpression in tumor
samples of low-grade glioma
9 and anaplastic astrocy-
toma
10 has been associated with poor prognosis. As
the EGFR signaling pathway is a key feature in glioma
progression, our aim was to perform comprehensive
tagging and analyzes of germline genetic variants in
EGF and EGFR to evaluate if these genes play a role
in glioblastoma prognosis.
Material and Methods
Study Subjects
The initial study set was based on 176 cases from Sweden
andDenmarkdiagnosedwithglioblastoma(International
Classiﬁcation of Diseases [ICD] code 94403) between the
years 2000 and 2004, as part of the international
Interphone study.
11 Association studies have previously
been done on this material, and the cases’ ascertainment
details are described in previous publications.
5,12
Eligible cases were invited by letter or personally to take
part in the study. If no reply was received, a repeat
letter was sent or the potential participant was contacted
by telephone. Blood samples were collected from all
cases, and a pathology review was conducted by a
Swedish and Danish pathologist. The tumors were
graded and classiﬁed according to the WHO 2007 cri-
teria.
13 The age of the cases ranged between 20 and 69,
and there were 109 men and 67 women. The mean age
at diagnosis was 54 and the median age at diagnosis was
56 years. For these cases, all medical records were
retrieved and detailed clinical data were collected, includ-
ing date of diagnosis, follow-up date(s), surgery, radio-
therapy treatment, and treatment programs including
chemotherapy. In 33 cases, only incomplete information
on treatment was available; chemotherapy only in 23
cases, radiotherapy (1 case), and/or surgery in 9 cases.
In 6 of these cases, we were not able to collect any treat-
ment data at all (3%). All cases were followed from date
of diagnosis until either date of death or date of last
follow-up in the patient records. In 10 cases, follow-up
was not available and, in an additional 11 cases, we
lacked information on the date of diagnosis, leaving 155
cases for the ﬁnal analysis (Table 1). The missing values
were due to lack of available medical reports as the
patients moved several times, which did not enable the
collection of complete follow-up information.
Conformational analyses on signiﬁcant SNPs in EGF
were made using a data set of 638 glioblastoma cases
recruited from 1990 to 2008, with follow-up until April
2009, from The University of Texas M. D. Anderson
Cancer Center (MDACC). All cases were Caucasians,
had a conﬁrmed diagnosis of primary glioblastoma
(ICD-9 codes 94403), and were at least 18 years of age
at the time of diagnosis. The male/female ratio was
397/241, the mean age at diagnosis was 52.3 years, and
median age at diagnosis was 54 years. In this data set,
586 cases were deceased and 52 cases were alive at the
last follow-up. Cases were excluded if they had a prior
diagnosis of cancer or if they had undergone prior treat-
mentfortheirglioblastoma(radiotherapy,chemotherapy,
or surgical resection). The cases were followed from date
of diagnosis until either date of death or the last contact
date for still alive patients.
Table 1. Distribution of clinical characteristics of treatment and survival in 176 glioblastoma patients from Sweden and Denmark
Sweden (n 5 108) Denmark (n 5 68) Total (n 5 176)
Total (n [%]) Missing (n [%]) Total (n [%]) Missing (n [%]) Total (n [%]) Missing (n [%])
Survival (mos)
Mean 16.1 15.1 15.7
Median (range) 12.4 (2.1–71.8) 14.2 (1.0–51.9) 12.8 (1.0–71.8)
Gross total resection 6 (5.6) 1 (1.5) 169 (96.0) 7 (4.0)
Yes 26 (24.1) 24 (35.3) 50 (29.6)
No 76 (70.4) 43 (63.2) 119 (70.4)
Chemotherapy 13 (12.0) 10 (14.7) 153 (86.9) 23 (13.1)
Yes 69 (63.9) 14 (20.6) 83 (54.2)
No 26 (24.1) 44 (64.7) 70 (45.8)
Radiotherapy 7 (6.5) 2 (2.9) 167 (94.9) 9 (5.1)
Yes 90 (83.3) 57 (83.8) 147 (88.0)
No 11 (10.2) 9 (13.2) 20 (12.0)
Number of deaths 92 (85.2) 10 (9.3) 66 (97.1) 158 (89.8) 10 (5.7)
Sex 176 (100)
Male 66 (61.1) 43 (63.2) 109 (61.9)
Female 42 (38.9) 25 (36.8) 67 (38.1)
Age at diagnosis median (yrs) 56 (22–69) 56 (39–69) 56 (22–69)
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We accessed the SNPs selected for genotyping from the
public dbSNP (http://www.ncbi.nih.gov), HapMap
(http://www.hapmap.org/), and SNPper (http://snpper.
chip.org/). Speciﬁc SNPs were chosen for genotyping in
order to tag the linkage disequilibrium (LD) and to
acquire genotype information for a larger number of
SNPs within and surrounding the analyzed genes. A com-
plete tagging of EGF and EGFR was based on the
Haploview software (http://www.broad.mit.edu/mpg/
haploview) with a minimum r
2 of 0.9. To ensure an LD
to infer information on all SNPs captured by the tag set
and to obtain a data set with sufﬁcient power, we chose
a minimum minor allele frequency of 5% in the
HapMap CEPH (CEU) Utah residents with ancestry
from Northern and Western Europe. DNA was extracted
from samples using conventional methodologies and
quantiﬁed using PicoGreen (Invitrogen Corp.).
Genotyping
Genotyping validation was ﬁrst made on 14 family
trios, in total 42 individuals, from whom genotype
data are available through the HapMap consortium.
Concordance analysis, using the HapMap data, and
analysis of the parent–offspring compatibility with the
produced genotypes were performed.
Genotypingwasperformed twiceon 90samples forall
the SNPs in the study, as an internal concordance analy-
sis. Three different DNA samples were used in quadrupli-
cate on each 364-well plate that was analyzed. The
success rate was calculated for each SNP genotyping
assay as the number of genotypes retrieved over the poss-
ible number of genotypes. The concordance between the
HapMap data and the data produced on the HapMap
trios was 100% for all the SNPs. No parent–offspring
incompatibility was found for any of the SNP data.
The concordance for the 90 repeated samples was
100%.Thethreerepeatedsamplesonalldifferentanalysis
units showed concordant genotypes for all assays, at all
instances when they were genotyped. The success rate
forthedifferentSNPassaysspannedfrom96.5%to98%.
In all, 30 SNPs in EGF and 89 SNPs in EGFR were
included in the genotyping analyzes, all passing the con-
cordance and validation steps, and with a call rate at
80% or higher.
All SNPs were genotyped using matrix-assisted laser
desperation/ionization time-of-ﬂight mass spectrometry
(Sequenom Inc.). Assays for all SNPs were designed
using SpectroDESIGNER software (Sequenom Inc.). All
SNPs were genotyped using the iPLEX assays. The ampli-
ﬁcation was performed in a total volume of 5 mL contain-
ing10 ngofgenomicDNA,100 nMofeachampliﬁcation
primer, 500 mM of dNTP mix, 1.625 mM MgCl2,a n d
5.5 units of HotStarTaq DNA Polymerase (Qiagen Inc.).
The reaction was subjected to the following PCR con-
ditions: a single cycle of denaturation at 958Cf o r1 5
minutes, followed by 45 cycles at 948C for 20 seconds,
568C for 30 seconds, 728C for 60 seconds, and a ﬁnal
extension at 728C for 3 minutes. The allele-speciﬁc
extension was performed in at a total volume of 9 mL
using 5 pmol of extension primer and the Mass
EXTEND Reagent Kit and cleaned using SpectroCleaner
(Sequenom Inc.). Products from primer-extension reac-
tions were loaded on a 384-element chip nanoliter pipet-
ting system (Sequenom Inc.) and analyzed on a
MassARRAY mass spectrometer (Bruker Daltonik
GmbH). Data were analyzed independently by two
personsusingtheSpectroTypersoftware(SequenomInc.).
The MDACC cases were genotyped in the Illumina
610k array and 4 of the 7 EGF polymorphisms were
available on the 610k array for conﬁrmation.
Statistical Methods
Statistical analyzes were undertaken by using SPSS soft-
ware, and survival time was estimated as hazard ratios
(HRs) for carrying different genetic variants in the
EGF or EGFR gene using the Cox-regression model
and having the major allele as the categorical variable.
All HRs were adjusted for other factors that could
affect glioblastoma outcome such as country, sex, age,
surgery (gross-total resection or not), radiotherapy,
and chemotherapy.
Results
We evaluated 30 tagging SNPs in EGF and 89 tagging
SNPs in EGFR for association with survival in glioblas-
toma cases.
In the EGF gene, we found 7 SNPs associated with
survival, 2 of the SNPs were located in the promoter
region and the remaining 5 were located in introns 5,
7, 10, 11, and 13 (Table 2). In all these SNPs, there
was an association with shorter survival except for the
promoter SNP, rs6533477, where there were a hetero-
zygote association with shorter survival and no homo-
zygote variant for the minor allele. All 7 polymorphisms
associated with poor prognosis are located on haplotype
block 4 and are in LD with the previously identiﬁed
functional polymorphism 61 A/G, EGF SNP
rs4444903. The EGF SNP, rs3796944, had an HR of
2.93 (95% CI: 1.60–5.37) with a median survival time
of 8.6 months for homozygote cases for the minor
allele compared with 14.7 months for the major allele A.
Similar results with the minor allele associated with
shorter survival could be seen in all SNPs when analyz-
ing the Swedish and Danish data sets separately,
see example in Table 3.
Four of the SNPs that were signiﬁcant in EGF
(rs17238095, rs3796944, rs9992755, and rs11568994)
were available for conﬁrmation in the MDACC patient
cohort; however, none reached statistical signiﬁcance
(Table 4). In the whole data set, a nonsigniﬁcant trend
of decreased survival was seen for rs3796944, the
variant allele HR ¼ 1.19 95% CI (0.94–1.51), with a
24.5 month median survival for the common allele and
18.5 months for the rare variant (Table 5). When com-
paring the characteristics of the 2 study groups, we
saw a minor discrepancy in age at diagnosis (median
Sjo ¨stro ¨m et al.: EGF polymorphisms and glioblastoma outcome
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rs number Region Major allele Genotype No. (%) HR (95% CI) P value Median survival time
rs17238095 Promoter region C CC 77 (51.7) 1.0 14.4
CT 67 (45) 1.37 (0.93–2.03) .116 12.8
TT 5 (3.4) 9.29 (2.35–36.78) .001* 8.6
rs6533477 Promoter region A AA 133 (89.3) 1.0 13.2
AG 16 (10.7) 2.09 (1.16–3.76) .014* 11.7
rs3796944 Intron 5 A AA 61 (40) 1.0 14.7
AG 70 (45.8) 1.32 (0.88–1.96) .177 12.8
GG 22 (15.2) 2.93 (1.60–5.37) .0005* 8.6
rs9992755 Intron 7 A AA 72 (46.8) 1.0 14.7
AG 70 (45.5) 1.45 (0.99–2.12) .059 12.4
GG 12 (7.8) 3.13 (1.47–6.65) .003* 8.6
rs1860129 Intron 10 G GG 60 (39) 1.0 14.7
CG 72 (46.8) 1.30 (0.87–1.93) .2 13.0
CC 22 (14.3) 2.87 (1.57–5.24) .001* 8.6
rs2298989 Intron 11 T TT 56 (36.4) 1.0 15.1
CT 73 (47.4) 1.47 (0.98–2.19) .06 13.0
CC 25 (16.2) 2.19 (1.24–3.88) .007* 8.6
rs11568994 Intron 13 G GG 73 (47.7) 1.0 14.7
AG 67 (43.8) 1.38 (0.94–2.04) .1 12.6
AA 13 (8.5) 2.65 (1.28–5.51) .009* 8.9
Patients diagnosed between 2000 and 2004, in Sweden and Denmark, as part of the Interphone study. All hazard ratios (HR) are adjusted
for country, sex, age, surgery, radiotherapy, and chemotherapy. Number (No.) of cases analyzed varies due to missing treatment data or
genotyping failure.
*Signiﬁcant ﬁnding P , .05.
Table 3. Comparison between the Swedish and Danish results for the EGF SNP rs3796944 located in intron 5, major allele A
Country Genotype No. (%) HR (95% CI) P value
Sweden and Denmark AA 61 (40) 1.0
AG 70 (45.8) 1.32 (0.88–1.96) .177
GG 22 (15.2) 2.39 (1.60–5.37) .0005*
Sweden AA 39 (44.8) 1.0
AG 35 (40.2) 0.92 (0.53–1.58) .759
GG 13 (14.9) 2.10 (1.02–4.32) .044*
Denmark AA 22 (33.3) 1.0
AG 35 (53.0) 1.62 (0.85–3.06) .140
GG 9 (13.6) 5.95 (1.89–18.77) .002*
Hazard ratios (HR) are adjusted for country, sex, age, surgery, radiotherapy, and chemotherapy. Number (No.) of cases analyzed varies
due to missing treatment data or genotyping failure.
*Signiﬁcant ﬁnding P , .05.
Table 4. Validation on 4 of the signiﬁcant EGF SNPs in a data set of 638 glioblastoma cases recruited at MDACC, from 18 years of age,
recruited from 1990 to 2008, with follow-up until April 2009
Region Major allele Genotype No. (%) HR (95% CI) P value Median survival time
rs17238095 Promoter region C CC 319 (54.1) 1.0 24.1
CT 230 (39.0) 1.09 (0.93–1.31) .632 23.4
TT 41 (6.9) 1.28 (0.93–1.77) .163 17.2
rs3796944 Intron 5 A AA 200 (33.9) 1.0 24.5
AG 284 (48.1) 1.09 (0.91–1.32) .446 23.8
GG 106 (18.0) 1.19 (0.94–1.51) .231 18.6
rs9992755 Intron 7 A AA 252 (42.7) 1.0 24.1
AG 272 (46.1) 1.09 (0.90–1.28) .561 23.1
GG 66 (11.2) 1.06 (0.81–1.38) .881 19.6
rs11568994 Intron 13 G GG 251 (42.5) 1.0 24.2
AG 274 (46.4) 1.16 (0.88–1.53) .342 23.5
AA 65 (11.0) 1.05 (0.87–1.25) .876 18.1
All hazard ratios (HRs) are adjusted for sex and age.
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median survival time (12.8 months in our dataset vs 15
in the conﬁrmation set) between the two groups with a
younger age of diagnosis and longer survival time in
the conﬁrmation set. Since the survival was signiﬁcantly
longer in the MDACC data set, we assumed that one
explanation for this could be a large amount of second-
ary glioblastomas among the younger population as the
mean age differed between the populations. We there-
fore analyzed the SNPs using only the cases over 50
years of age in the conﬁrmation dataset, leaving 374
cases to analyze, with 363 deceased in the group.
Median survival time in the new group was 14 months
and median age atdiagnosiswas58 years.When restrict-
ing the analyses to cases 50 years or older to enrich for
primary glioblastoma, the association of rs3796944
was marginally signiﬁcant, HR ¼ 1.32, 95% CI (0.99–
1.79). The conﬁrmation data set was adjusted for sex
and age but not for treatment and surgery (Table 5).
In the EGFR gene we found 4 SNPs associated with
survival, all located in different introns and haplotype
blocks throughout the gene (Table 6). As 89 polymorph-
isms were tested in the gene, this is not more signiﬁcant
associations than would be expected by chance.
Discussion
This study is, to our knowledge, the ﬁrst to perform a
comprehensive tagging of the EGF and EGFR genes
and estimates their prognostic impact, ﬁnding an associ-
ation with EGF polymorphisms in haplotype block 4
and glioblastoma prognosis. Seven SNPs within the
same LD block in EGF were associated with prognosis
in glioblastoma cases with a consistent association in
all the EGF genetic variants between the minor allele
and poor prognosis. When analyzing 4 of the signiﬁcant
EGF SNPs in a larger conﬁrmation set of 638 glioblas-
toma, we saw the same trend with minor allele associ-
ation to shorter survival, but the results were only
marginally signiﬁcant when analyzing patients older
than 50, which was performed to adjust for the discre-
pancies in age of the ﬁrst and second data sets. The
differences in the data sets could also, of course,
depend on the variability of the data sets.
There have been only a few studies evaluating prog-
nostic factors for glioblastoma. Previous studies have
shown an association between young age at diagnosis,
high Karnofsky performance score (KPS), and longer
survival.
14 More frequent hypermethylation of the
Table 5. Validation analyses on 4 of the signiﬁcant EGF SNPs in a data set of 374 glioblastoma cases recruited at MDACC, only including
patients older then 50, recruited from 1990 to 2008, with follow-up until April 2009
rs number Region Major allele Genotype No. (%) HR (95% CI) P value Median survival time
rs17238095 Promoter region C CC 192 (51.3) 1.0 18.9
CT 156 (41.7) 1.19 (0.97–1.48) .096 17.4
TT 26 (7.0) 1.41 (0.95–2.11) .088 15.0
rs3796944 Intron 5 A AA 122 (32.6) 1.0 19.6
AG 179 (47.9) 1.21 (0.96–1.52) .096 17.8
GG 73 (19.5) 1.32 (0.99–1.78) .065 15.1
rs9992755 Intron 7 A AA 150 (40.1) 1.0 18.1
AG 183 (48.9) 1.10 (0.89–1.34) .561 18.1
GG 41 (11.0) 1.09 (0.79–1.55) .741 17.4
rs11568994 Intron 13 G GG 150 (40.1) 1.0 18.4
AG 182 (48.7) 1.11 (0.90–1.37) .448 18.1
AA 42 (11.2) 1.24 (0.89–1.75) .282 16.1
All hazard ratios (HRs) are adjusted for sex and age.
Table 6. SNPs in the EGFR gene associated with glioblastoma prognosis in the Swedish and Danish data set
rs number Region Major allele Genotype No. (%) HR (95% CI) P value Median survival time
rs980653 Intron 1 C CC 100 (66.2) 1.0 11.7
CT 47 (31.1) 1.07 (0.99–1.14) .079 14.2
TT 4 (2.6) 0.60 (0.40–0.89) .01* 9.2
rs730437 Intron 4 A AA 45 (29.6) 1.0 10.8
AC 67 (44.1) 0.53 (0.34–0.84) .007* 13.2
CC 40 (26.3) 0.50 (0.29–0.87) .013* 15.1
rs4947986 Intron 7 G GG 72 (47.7) 1.0 14.1
AG 63 (41.7) 1.00 (0.67–1.48) .98 13.2
AA 16 (10.6) 2.21 (1.17–4.18) .014* 9.9
rs9642393 Intron 19 T TT 97 (64.2) 1.0 12.8
CT 47 (31.1) 1.28 (0.86–1.90) .226 13.2
CC 7 (4.6) 3.44 (1.25–9.51) .017* 9.6
Hazard ratios (HRs) are adjusted for country, sex, age, surgery, radiotherapy, and chemotherapy. Number (No.) of cases analyzed varies
due to missing treatment data or genotyping failure.
*Signiﬁcant ﬁnding P , .05.
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with long-term survival, especially when treatment is
given with temozolamide in combination with radio-
therapy.
15 Although signaling pathways in glioblastoma
are complicated networks, there are key factors such as
dysregulation of growth factor signaling via ampliﬁca-
tion and mutational activation of receptor tyrosine
kinase genes (eg, EGFR and ERBB2), activation of the
phosphatidylinositol-3-OH kinase (PI3K/AKT)
pathway and inactivation of the p53 and retinoblastoma
tumor suppressor pathways.
16
A limited number of studies have investigated the
role of EGF and EGFR polymorphisms and prognosis.
Previous studies have been small and have not analyzed
all of the tagging SNPs in EGF but have focused on one
functional polymorphism, the 61 A/G. This polymorph-
ism is situated in the 50 untranslated region of the gene,
where the uncommon 61G allele has a higher function
for expression of EGF when compared with the 61A
allele.
2 Higher levels of EGF have been associated
with tumor progression and angiogenesis.
17 A small
study of 42 glioblastoma patients showed that patients
with AG and GG genotypes had higher levels of EGF in
the tumor and were more likely to recur and progress.
1
In this study, they collected data on gender, age at diag-
nosis, surgery, and postoperative treatment (radiation-
and chemotherapy) and found no difference in these
variables when they compared cases by the different
genotypes.
1 In a larger study of 197 glioma patients,
with a mean age at diagnosis of 48.5 years, the EGF
61 A/G was associated with glioma risk, but not
overall survival of glioblastoma patients; however,
here the data are only adjusted for gender and age,
without consideration of the extent of surgery or post-
operative treatment.
7 One reason for the difference in
results compared with our study could be the younger
age in their study population. In a more recent study
of 209 glioblastoma patients, the EGF 61 A/G poly-
morphism was found to be neither a clear prognostic
factor for survival nor a risk factor for glioblastoma
but with some impact on progression-free survival
with a mean age of the patients similar to ours, 56.2
years.
2 In that study, adjustment for surgery and post-
operative treatment was performed but not for radio-
therapy and chemotherapy separately. The details of
the types of chemotherapy were not given in the
report. Thus, the results so far are unclear and incon-
clusive possibly because of lack of power and imprecise
treatment information. The sample sizes are small,
resulting in a lack of statistical power. In our study
we observed a consistent association over the complete
haplotype block harboring the EGF 61 A/G poly-
morphism. This is the most likely functional candidate
genetic variant explaining the association with poor
prognosis; however, other functional variants within
the same LD block cannot be ruled out. Nevertheless,
these results are in line with the proven functionality
of increased EGF expression in blood and tumor
observed in previous studies.
1,2 The impact of the poly-
morphism could be codependent on the existence of the
EGFRvIII mutation, as the EGF signaling has less
impact on tumors with autophosphorylated mutations
with autocrine loops for cell signaling.
18 The preva-
lence of EGFR mutations is not known in our data
set or in the French study.
2 MDACC was unable to
adjust for treatment, as we did with the initial 155
cases, but is still marginally signiﬁcant in the patients
older than 50 years. As the time period for recruitment
is later in the MDACC, they might have a higher rate
of temozolamide-treated patients. Further conﬁrmation
is necessary in separate data sets with similar treatment
information to establish EGF as a prognostic factor.
Ampliﬁcation and/or overexpression of EGFR have
been found in about 50% of malignant glioma tumors;
however, the prognostic value is unclear. One study
has shown an association with better prognosis with
EGFR expression when examining 403 cases with glio-
blastoma and adjusting for gender, age, and treatment.
However, in the same study, they showed a signiﬁcantly
worse prognosis for astrocytoma with EGFR tumor
overexpression. For both glioblastoma and astrocytoma,
cases with EGFR overexpression were more strongly
associated with survival than EGFR ampliﬁcation.
10 In
a small study of 41 glioblastoma patients over the age
of 50 with available treatment data, no association
between EGFR ampliﬁcation and prognosis was
found;
19 the same results were seen in a larger study of
715 glioblastoma cases.
20 In a group of 55 glioblastoma
patients with long-term survival of more than 36
months, with treatment data available, a trend toward
less EGFR ampliﬁcation was seen; however, this was
not statistically signiﬁcant.
15 In a previous study from
our group, we showed in small series of cases that low-
grade gliomas with high EGFR protein expression had
signiﬁcantly shorter survival than those with no or low
protein expression.
9 Therefore, tumor studies on EGFR
have been inconsistent in prognostic relevance, and no
studies, to our knowledge, have been published on the
complete genetic variance of EGFR and glioblastoma
prognosis.
Among our studied polymorphisms, the functionally
most interesting and signiﬁcant SNP in EGFR is
rs4947986, located in the exon7/intron border. In 20–
30% of glioblastomas, the extracellular part of the
EGFR is mutated (EGFRvIII) with a deletion of exons
2–7, and the associated EGFR SNP rs4947986 is
located at the break point of this common deletion,
which could imply a functional role for prognosis in
patients with glioblastoma. Some studies have identiﬁed
Y845 as a phosphorylation site speciﬁcally activated by
ionizing radiation.
21 Therefore, different genetic var-
iants in EGFR could be hypothesized to have different
functional properties in response to radiotherapy,
which could give a functional explanation to differences
in prognosis seen in our study. However, the associated
SNPs in EGFR were similar to the estimated number of
false-positive, leaving chance alone as the most likely
explanation to the ﬁndings in EGFR.
This study provides some evidence for EGF poly-
morphism having a prognostic association for glioblas-
toma. Additional large studies with robust tagging of
the complete gene variation of EGF and EGFR are
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ging results. As with all association studies, the consist-
ency with functionality, results of previous studies, the
power to detect association, and the possibility of false-
positive ﬁndings must be taken into consideration. In
this study, we have found an association of EGF and
glioblastoma survival, with a clear functional genetic
variation in the haplotype block and consistent with
some,
1,7 but not all previous studies.
2 We observed a
nonsigniﬁcant association in the same direction in the
conﬁrmation set; however, no treatment datawere avail-
able to adjust for.
It is of importance to ﬁnd robust genetic markers that
could identify the right patients suitable for a speciﬁc
treatment. A full comparison of the functional poly-
morphism in prospective studies with similar treatment
given will elucidate the role for EGF polymorphisms
as an independent prognostic factor.
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